Linked Life Data

19437350

Source:http://linkedlifedata.com/resource/pubmed/id/19437350

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2009-5-13
pubmed:abstractText
Corneal neovascularization causes deterioration of visual acuity and increases surface irregularities. Various techniques have been employed to help control the progression of corneal neovascularization; bevacizumab is a medication that targets the specific pathway of corneal neovascularization. The Boston Ocular Surface Prosthesis (BOSP) is a large diameter contact lens that aids in maintaining corneal surface integrity and may serve as a delivery system for topical bevacizumab. This paper reviews five patients who were treated with topical bevacizumab in their BOSP. All patients demonstrated improvement in their visual acuity and clinical exam. No adverse reactions were noted.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1744-5205
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
24
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
149-55
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:articleTitle
The Boston Ocular Surface Prosthesis as a novel drug delivery system for bevacizumab.
pubmed:affiliation
Ophthalmic Education, Massachusetts Eye and Ear Infirmary, 243 Charles St., Boston, MA 02114, USA. mira_lim@meei.harvard.edu
pubmed:publicationType
Journal Article, Case Reports